VYNE Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of VYNE Therapeutics generated cash of -$25,341,000, which is more than the previous year. Cash used in financing activities reached the amount of $82,394,000 last year. Net change in cash is therefore -$301,000.
Cash Flow
| 2015 | -4.18M | 0 | 47.71M |
|---|---|---|---|
| 2016 | -2.29M | -37.49M | 0 |
| 2017 | -28.24M | -15.06M | 49.49M |
| 2018 | -52.73M | -33.87M | 125.91M |
| 2019 | -65.10M | 41.37M | 4.99M |
| 2020 | -137.08M | 89.10M | 61.80M |
| 2021 | -56.36M | 1.02M | 39.77M |
| 2022 | -29.2M | 15.66M | 1.65M |
| 2023 | -25.34M | -57.35M | 82.39M |
VYNE Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 30.97M | 42.85M | 58.41M | 44.58M | 49.51M | 10.20M | 4.02M | 43.80M | 273K |
Operating activities | |||||||||
Net income | -28.45M | -23.21M | -73.32M | -255.56M | -73.70M | -51.44M | -29.07M | -14.06M | -4.60M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 0 | 72K | 109K | 341K | 700K | 22K | 8K | 4K | 0 |
Stock-based compensation expense | 3.30M | 4.29M | 8.08M | 18.1M | 6.70M | 0 | 1.45M | 573K | 65K |
| Deferred income tax benefit | 3.30M | 4.29M | 8.08M | 18.1M | 6.70M | 0 | 1.45M | 573K | 65K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 405K | 11.21M | 7.70M | -17.13M | 1.35M | 786K | -786K | 0 | 0 |
Inventories | 0 | 97K | 113K | -6.04M | -1.35M | 2.76M | 1.18M | 0 | 0 |
Accounts payable | -559K | -8.68M | -2.67M | -12.97M | 481K | 825K | 620K | 889K | 0 |
Cash generated by operating activities | -25.34M | -29.2M | -56.36M | -137.08M | -65.10M | -52.73M | -28.24M | -2.29M | -4.18M |
Investing activities | |||||||||
Purchases Of Investments | -62.35M | 0 | 0 | -38.64M | -83.39M | -126.7M | -64.14M | -55.30M | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | -113K | -11K | -140K | -27K | -31K | 0 |
Acquisitions Net | 5M | 15.66M | 0 | 38.64M | 40K | 0 | -25K | 0 | 0 |
Cash generated by investing activities | -57.35M | 15.66M | 1.02M | 89.10M | 41.37M | -33.87M | -15.06M | -37.49M | 0 |
Financing activities | |||||||||
Common Stock Issued | 82.82M | 1.47M | 75.98M | 61.63M | 4.52M | 125.41M | 50.32M | 0 | 47.71M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -360K | 0 | -294K | -141K | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -36.43M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 82.39M | 1.65M | 39.77M | 61.80M | 4.99M | 125.91M | 49.49M | 0 | 47.71M |
Net Change In Cash | -301K | -11.88M | -15.56M | 13.83M | -18.73M | 39.30M | 6.17M | -39.78M | 43.53M |
Cash at end of period | 30.67M | 30.97M | 42.85M | 58.41M | 30.77M | 49.51M | 10.20M | 4.02M | 43.80M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |